Assessment of the differentiated aspiration process of palivizumab

Acta Paulista de Enfermagem

Rosemeire Sartori De Albuquerque¹  Corintio Mariani Neto¹  Gisleine Aparecida De Castro Arone¹  Ana Aparecida Sanches Bersusa¹  Vanessa Peres Leandro¹ 

关键词: Vaccine;    Maternal-child nursing;    Nursing care;    Respiratory tract infections/prevention & control;    Respiratory syncyal viruses/immunology;    Antibodies;    monoclonal/ therapeutic use;    Antibodies;    monoclonal/economic;    Child;    Vacina;    Enfermagem materno-infantil;    Cuidados de enfermagem;    Infecções respiratórias/prevenção & contrele;    Virus sinciais respiratórios/imunologia;    Anticorpos monoclonais/uso terapêutico;    Anticorpos monoclonais/economia;    Criança;   

DOI  :  10.1590/1982-0194201400014

来源: SciELO

【 摘 要 】

OBJECTIVE: Assess the differentiated aspiration process of palivizumab, from planning to administration, and from the patient's profile to obtained savings as a result of the optimization of doses.METHODS: Cross-sectional study carried out by means of secondary data obtained from the medical records of 858 children. Variables of the study were as follows: information on the profile of cared children, amount of acquired and administered doses, vaccination procedure, and optimized doses. Data were extracted from care management reports.RESULTS: The innovative technique and the vaccination planning allowed for 98 children to be favored by leftovers of the medication, implying savings of R$ 1.144.347,52 in 2012 and 2013.CONCLUSION: The employment of the differentiated aspiration process favored the availability of the medication to 54 children other than those previously programmed, and the application of 78 leftovers. The establishment of a previous management planning process of programmed contents to be administered to children, in compliance with their profile, especially their body weight, favored the inclusion of other admitted newborns. The systematization process of the team work toward the administration of palivizumab implied the reduction of public expenditures.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License